Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health, Inc. (NYSE: TDOC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its virtual care business, financial condition and governance. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe material events, segment performance and capital structure decisions.
Recent Form 8-K filings for Teladoc Health have addressed topics such as quarterly financial results, preliminary earnings announcements, entry into a senior secured revolving credit facility, amendments to the company’s 2023 Employment Inducement Incentive Award Plan, and changes in executive leadership and Board composition. For example, the company has reported on its second and third quarter 2025 results, including revenue by type and geography, Integrated Care and BetterHelp segment performance, and adjusted EBITDA. It has also disclosed the establishment of a five-year revolving credit facility and amendments to its inducement equity plan to increase the number of shares reserved for issuance.
On this page, investors can review Teladoc Health’s SEC filings to understand how the company reports revenue from access fees and other sources, how it presents non-GAAP measures such as adjusted EBITDA, and how it describes its capital allocation priorities. Filings also provide information on leadership transitions, director decisions, and compensatory arrangements, including inducement awards of restricted stock units and performance stock units.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports. Users can quickly see highlights related to Teladoc Health’s Integrated Care and BetterHelp segments, credit agreements, equity plans, and governance changes, while still being able to open the full SEC documents for complete details.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, reported a mix of stock sales and equity awards. Bliss sold 26,647 shares of common stock in an open-market transaction at $5.117 per share to cover tax withholding obligations related to vesting equity awards, and held 84,747 common shares afterward.
On March 1, 2026, Bliss received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc share, generally vesting one-third on the first anniversary of the grant date with the balance in eight quarterly installments. Around February 27, 2026, multiple restricted stock unit and performance stock unit awards were exercised or earned, including 27,458 performance stock units determined using metrics tied to Teladoc’s 2025 financial results, all converting to common stock on a one-for-one basis.
Fernando Madeira Rodrigues reported a proposed sale of 25,086 common shares tied to restricted stock vesting on 03/01/2026. The filing lists the shares as to be sold through Fidelity Brokerage Services LLC on the NYSE.
It also discloses prior sales in the past three months: 4,209 shares sold on 12/03/2025 for $31,483.32 and 16,314 shares sold on 03/02/2026 for $83,473.84.
Teladoc Health executive Carlos Nueno reported multiple equity transactions involving Teladoc Health, Inc. common stock and equity awards. On March 2, 2026, he sold 20,165 shares of common stock in an open‑market transaction at $5.117 per share, with a footnote stating the sale was to cover tax withholding obligations from vesting awards.
On March 1, 2026, he received a grant of 173,010 restricted stock units with each unit representing a contingent right to one Teladoc share. On February 27, 2026, several blocks of restricted stock units and performance stock units converted into common stock on a one‑for‑one basis, increasing his shareholdings. After these transactions, he directly owned 50,595 common shares.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported multiple stock transactions involving common shares and restricted stock units. He sold 16,314 common shares at $5.117 per share and 25,086 shares at $4.982 per share, totaling 41,400 shares sold.
Footnotes state these shares were sold to cover tax withholding obligations tied to vesting of restricted stock units and were executed under a Rule 10b5-1 trading plan adopted on November 3, 2025. Rodrigues also reported grants and exercises of restricted stock units, including 181,661 units granted on March 1, 2026, which each represent a contingent right to receive one share of Teladoc common stock and vest over time in scheduled installments.
Filer submitted a Form 144 reporting proposed sales of common stock related to compensation vesting. The filing lists 16,314 shares under "Securities To Be Sold" with a date of 02/27/2026. It also records prior sales: 2,324 shares on 12/02/2025 and 4,209 shares on 12/03/2025.
The broker address shown is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI. The excerpt includes an NYSE listing and a numeric reference 178,396,434 alongside 03/02/2026.
Teladoc Health (TDOC) insider sale notice: a proposal to sell 50,145 common shares tied to restricted stock vesting on 02/27/2026 as compensation. The filing also records a prior sale of 17,138 common shares on 12/11/2025 by Charles Divita for $130,836.63.
TDOC submitted a Form 144 notice reporting 26,647 shares of Common stock associated with a restricted stock vesting event on 02/27/2026; the filing lists Fidelity Brokerage Services LLC as the selling broker and the exchange as NYSE. The filing notes a prior sale by Kelly Bliss of 4,582 shares on 12/02/2025 for $34,311.39.
Tdoc, Inc. filed a Form 144 disclosing a proposed sale of 27,083 common shares. The securities are described as Restricted Stock Vesting with a vesting/transaction date of 02/27/2026 and are listed as issuer/compensation-related.
The filing also reports prior sales of 5,720 common shares on 12/02/2025 by Adam Vandervoort. The notice names Fidelity Brokerage Services LLC as the broker and is tied to NYSE-listed common stock.
Carlos Nueno Plana filed a Form 144 to sell 20,165 common shares as restricted stock vests. The filing lists sale routing through Fidelity Brokerage Services LLC and notes the shares are tied to compensation and a vesting date of 02/27/2026. The filing also records a prior sale of 3,897 shares on 12/02/2025.
Teladoc Health outlines in its annual report how it operates a large-scale virtual care platform while remaining unprofitable. The company completed 17.1 million telehealth visits in 2025, serving approximately 102 million U.S. members across its Integrated Care and BetterHelp segments.
In 2025, Teladoc Health generated about 83% of consolidated revenue from recurring access fees, with the rest from visit fees and hardware and software for hospitals and health systems. It reported a net loss of $200.3 million for 2025 and an accumulated deficit of $16,430.2 million as of December 31, 2025, including non-cash goodwill impairments. The business depends heavily on a small group of large Clients, with the top five accounting for 19% of total revenue, and highlights regulatory, cybersecurity, competition, and privacy risks as key ongoing challenges.